Trevena Inc. - נכסים נקיים למניה בודדת TRVN

Trevena, Inc. (TRVN) generates revenue from the sale of non-opioid analgesics in hospitals, creating a moderate cash flow. On GURU.Markets, this linear chart of the current BVPS demonstrates capital dynamics, where the current level equals -22.14. Technological leadership in the CNS space is driven by the innovative drug Olinvyk, while patent protection and strict FDA regulations create significant barriers to entry for new players.

When screening assets, an investor evaluates the intrinsic value of a business through the difference between total assets and liabilities divided by the number of shares. For Trevena, Inc. (TRVN), which minimizes capital expenditures by outsourcing production and research, this metric reflects the actual volume of equity, allowing for the calibration of overpayment risks by analyzing the dynamics of the book value per common share.